X4 Pharmaceuticals Inc. (XFOR)
0.19
-0.01 (-2.71%)
At close: Apr 17, 2025, 3:59 PM
0.20
2.91%
After-hours: Apr 17, 2025, 07:56 PM EDT
-2.71% (1D)
| Bid | 0.19 |
| Market Cap | 33.13M |
| Revenue (ttm) | 2.56M |
| Net Income (ttm) | -37.45M |
| EPS (ttm) | -0.19 |
| PE Ratio (ttm) | -1 |
| Forward PE | -0.53 |
| Analyst | Buy |
| Ask | 0.21 |
| Volume | 899,048 |
| Avg. Volume (20D) | 3,323,867 |
| Open | 0.21 |
| Previous Close | 0.20 |
| Day's Range | 0.19 - 0.20 |
| 52-Week Range | 0.19 - 1.39 |
| Beta | 0.58 |
About XFOR
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and my...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 16, 2017
Employees 143
Stock Exchange NASDAQ
Ticker Symbol XFOR
Website https://www.x4pharma.com
Analyst Forecast
According to 3 analyst ratings, the average rating for XFOR stock is "Buy." The 12-month stock price forecast is $3, which is an increase of 1472.33% from the latest price.
Stock ForecastsNext Earnings Release
X4 Pharmaceuticals Inc. is scheduled to release its earnings on May 6, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago
-12.07%
X4 Pharmaceuticals shares are trading lower follow...
Unlock content with
Pro Subscription
2 months ago
-10.83%
X4 Pharmaceuticals shares are trading lower after the company announced a restructuring of its workforce and capital spending.
